CG Oncology Reports Q1 2026 Financial Results with Significant Cash Increase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CGON?
Source: seekingalpha
- Financial Performance: CG Oncology's Q1 2026 report reveals a GAAP EPS of -$0.71, with revenue reaching $1.08 billion, indicating ongoing challenges in achieving profitability despite substantial sales figures.
- Cash Position: As of March 31, 2026, the company reported cash, cash equivalents, and marketable securities totaling $1.1 billion, a significant increase from $742.2 million as of December 31, 2025, reflecting positive progress in its financing activities.
- Financing Activities: In Q1 2026, CG Oncology raised approximately $391.4 million in net proceeds from the sale of 6,941,407 shares through its at-the-market facility, which not only bolstered its cash flow but also demonstrated confidence from high-quality funds.
- Rating Downgrade: Despite the improved cash position, Seeking Alpha downgraded CG Oncology's quant rating, indicating market concerns regarding its reasonable valuation, which may negatively impact investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGON
Wall Street analysts forecast CGON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.180
Low
65.00
Averages
79.73
High
108.00
Current: 69.180
Low
65.00
Averages
79.73
High
108.00
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CG ONCOLOGY INC Reports Q1 2026 Net Loss of $0.71 per Share
- Financial Performance: The company reported a net loss of $0.71 per share for Q1 2026.
- Market Impact: The financial results may influence investor sentiment and stock performance moving forward.
See More
CG Oncology Reports Q1 Earnings with Significant Cash Position Growth
- Earnings Report: CG Oncology's Q1 GAAP EPS stands at -$0.71, indicating challenges in profitability that could impact investor confidence moving forward.
- Revenue Performance: The company reported revenue of $1.08 million for the first quarter, reflecting pressure in the market despite cash inflows, which may hinder growth prospects.
- Cash Position Growth: As of March 31, 2026, CG Oncology's cash, cash equivalents, and marketable securities totaled $1.1 billion, a significant increase from $742.2 million as of December 31, 2025, showcasing enhanced financing capabilities.
- Financing Activity: The company raised approximately $391.4 million in net proceeds from the sale of 6,941,407 shares through its at-the-market facility in Q1, indicating successful engagement with high-quality investors and bolstering its financial stability.
See More
CG Oncology Reports Q1 2026 Financial Results with Significant Cash Increase
- Financial Performance: CG Oncology's Q1 2026 report reveals a GAAP EPS of -$0.71, with revenue reaching $1.08 billion, indicating ongoing challenges in achieving profitability despite substantial sales figures.
- Cash Position: As of March 31, 2026, the company reported cash, cash equivalents, and marketable securities totaling $1.1 billion, a significant increase from $742.2 million as of December 31, 2025, reflecting positive progress in its financing activities.
- Financing Activities: In Q1 2026, CG Oncology raised approximately $391.4 million in net proceeds from the sale of 6,941,407 shares through its at-the-market facility, which not only bolstered its cash flow but also demonstrated confidence from high-quality funds.
- Rating Downgrade: Despite the improved cash position, Seeking Alpha downgraded CG Oncology's quant rating, indicating market concerns regarding its reasonable valuation, which may negatively impact investor confidence.
See More
CG Oncology Reports Q1 2026 Financial Results and Milestones
- BLA Submission Progress: CG Oncology has successfully completed the non-clinical and clinical modules for its first BLA submission, with completion expected in Q4 2026, ensuring market access in the HR BCG-unresponsive NMIBC space and enhancing future revenue potential.
- Clinical Trial Data: Topline data from the PIVOT-006 Phase 3 trial is anticipated in the first half of 2026, while initial results from the CORE-008 Phase 2 trial will be presented at the 2026 AUA meeting, potentially providing new treatment options and market opportunities for the company.
- Improved Financial Position: As of March 31, 2026, the company reported cash and cash equivalents of $1.1 billion, a significant increase from $742.2 million as of December 31, 2025, ensuring sufficient funding for operations through 2029 and boosting investor confidence.
- Strengthened Executive Team: In April 2026, Jim DeTore was appointed as Chief Financial Officer, bringing over 30 years of life sciences experience, which is expected to enhance the company's financing and investor relations strategies, supporting future growth.
See More
Kynam Capital Reduces Stake in CG Oncology
- Share Reduction Details: Kynam Capital sold 1,059,375 shares of CG Oncology in Q4 2026 for an estimated $43.84 million, indicating a cautious outlook on the company's future performance.
- Ownership Percentage Change: Following the sale, CG Oncology now represents 2.51% of Kynam's holdings, down from 6.0% in the previous quarter, reflecting a decline in investor confidence in the stock.
- Company Financial Overview: CG Oncology has a market capitalization of $5.5 billion, with annual revenue of only $4 million and a net loss of $160.1 million, highlighting its ongoing clinical-stage status and profitability challenges.
- Future Growth Potential: Despite these challenges, CG Oncology holds over $740 million in cash, providing runway until 2029, with upcoming Phase 3 data expected to significantly impact stock performance and investor sentiment.
See More
Kynam Capital Reduces Stake in CG Oncology
- Share Reduction Details: Kynam Capital sold 1,059,375 shares of CG Oncology in Q4, with an estimated transaction value of $43.84 million, reflecting a cautious market sentiment regarding the company's future performance.
- Position Value Change: Post-sale, Kynam's stake decreased to 945,830 shares, valued at $39.27 million at quarter-end, indicating a net position change of $41.50 million due to trading activity and price fluctuations.
- Company Financial Health: CG Oncology focuses on innovative therapies for bladder cancer, generating only about $4 million in annual revenue, yet boasting over $740 million in cash reserves, providing a runway into 2029 and demonstrating financial resilience.
- Market Outlook and Risks: Despite CG Oncology's stock rising over 130% in the past year, its future performance heavily relies on upcoming clinical trial data, necessitating investor caution regarding the high expectations priced into the stock.
See More
CG ONCOLOGY INC Reports Q1 2026 Net Loss of $0.71 per Share
- Financial Performance: The company reported a net loss of $0.71 per share for Q1 2026.
- Market Impact: The financial results may influence investor sentiment and stock performance moving forward.
See More
CG Oncology Reports Q1 Earnings with Significant Cash Position Growth
- Earnings Report: CG Oncology's Q1 GAAP EPS stands at -$0.71, indicating challenges in profitability that could impact investor confidence moving forward.
- Revenue Performance: The company reported revenue of $1.08 million for the first quarter, reflecting pressure in the market despite cash inflows, which may hinder growth prospects.
- Cash Position Growth: As of March 31, 2026, CG Oncology's cash, cash equivalents, and marketable securities totaled $1.1 billion, a significant increase from $742.2 million as of December 31, 2025, showcasing enhanced financing capabilities.
- Financing Activity: The company raised approximately $391.4 million in net proceeds from the sale of 6,941,407 shares through its at-the-market facility in Q1, indicating successful engagement with high-quality investors and bolstering its financial stability.
See More
CG Oncology Reports Q1 2026 Financial Results with Significant Cash Increase
- Financial Performance: CG Oncology's Q1 2026 report reveals a GAAP EPS of -$0.71, with revenue reaching $1.08 billion, indicating ongoing challenges in achieving profitability despite substantial sales figures.
- Cash Position: As of March 31, 2026, the company reported cash, cash equivalents, and marketable securities totaling $1.1 billion, a significant increase from $742.2 million as of December 31, 2025, reflecting positive progress in its financing activities.
- Financing Activities: In Q1 2026, CG Oncology raised approximately $391.4 million in net proceeds from the sale of 6,941,407 shares through its at-the-market facility, which not only bolstered its cash flow but also demonstrated confidence from high-quality funds.
- Rating Downgrade: Despite the improved cash position, Seeking Alpha downgraded CG Oncology's quant rating, indicating market concerns regarding its reasonable valuation, which may negatively impact investor confidence.
See More
CG Oncology Reports Q1 2026 Financial Results and Milestones
- BLA Submission Progress: CG Oncology has successfully completed the non-clinical and clinical modules for its first BLA submission, with completion expected in Q4 2026, ensuring market access in the HR BCG-unresponsive NMIBC space and enhancing future revenue potential.
- Clinical Trial Data: Topline data from the PIVOT-006 Phase 3 trial is anticipated in the first half of 2026, while initial results from the CORE-008 Phase 2 trial will be presented at the 2026 AUA meeting, potentially providing new treatment options and market opportunities for the company.
- Improved Financial Position: As of March 31, 2026, the company reported cash and cash equivalents of $1.1 billion, a significant increase from $742.2 million as of December 31, 2025, ensuring sufficient funding for operations through 2029 and boosting investor confidence.
- Strengthened Executive Team: In April 2026, Jim DeTore was appointed as Chief Financial Officer, bringing over 30 years of life sciences experience, which is expected to enhance the company's financing and investor relations strategies, supporting future growth.
See More
Kynam Capital Reduces Stake in CG Oncology
- Share Reduction Details: Kynam Capital sold 1,059,375 shares of CG Oncology in Q4 2026 for an estimated $43.84 million, indicating a cautious outlook on the company's future performance.
- Ownership Percentage Change: Following the sale, CG Oncology now represents 2.51% of Kynam's holdings, down from 6.0% in the previous quarter, reflecting a decline in investor confidence in the stock.
- Company Financial Overview: CG Oncology has a market capitalization of $5.5 billion, with annual revenue of only $4 million and a net loss of $160.1 million, highlighting its ongoing clinical-stage status and profitability challenges.
- Future Growth Potential: Despite these challenges, CG Oncology holds over $740 million in cash, providing runway until 2029, with upcoming Phase 3 data expected to significantly impact stock performance and investor sentiment.
See More
Kynam Capital Reduces Stake in CG Oncology
- Share Reduction Details: Kynam Capital sold 1,059,375 shares of CG Oncology in Q4, with an estimated transaction value of $43.84 million, reflecting a cautious market sentiment regarding the company's future performance.
- Position Value Change: Post-sale, Kynam's stake decreased to 945,830 shares, valued at $39.27 million at quarter-end, indicating a net position change of $41.50 million due to trading activity and price fluctuations.
- Company Financial Health: CG Oncology focuses on innovative therapies for bladder cancer, generating only about $4 million in annual revenue, yet boasting over $740 million in cash reserves, providing a runway into 2029 and demonstrating financial resilience.
- Market Outlook and Risks: Despite CG Oncology's stock rising over 130% in the past year, its future performance heavily relies on upcoming clinical trial data, necessitating investor caution regarding the high expectations priced into the stock.
See More
